These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 22824792

  • 1. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
    Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K.
    Oncogene; 2013 Jun 06; 32(23):2818-27. PubMed ID: 22824792
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
    Nesterenko I, Wanningen S, Bagci-Onder T, Anderegg M, Shah K.
    PLoS One; 2012 Jun 06; 7(11):e49219. PubMed ID: 23145127
    [Abstract] [Full Text] [Related]

  • 3. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.
    Cancer Biol Ther; 2011 Aug 15; 12(4):335-48. PubMed ID: 21785270
    [Abstract] [Full Text] [Related]

  • 4. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
    Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, Hasselblatt M, Paulus W, Fuller G, Wolff JE, Gopalakrishnan V.
    J Neurooncol; 2009 Jul 15; 93(3):303-18. PubMed ID: 19148581
    [Abstract] [Full Text] [Related]

  • 5. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
    Redjal N, Zhu Y, Shah K.
    Stem Cells; 2015 Jan 15; 33(1):101-10. PubMed ID: 25186100
    [Abstract] [Full Text] [Related]

  • 6. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK, Kurzrock R, Shankar S.
    Mol Cancer Ther; 2010 Dec 15; 9(12):3254-66. PubMed ID: 21041383
    [Abstract] [Full Text] [Related]

  • 7. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.
    Cingöz A, Ozyerli-Goknar E, Morova T, Seker-Polat F, Esai Selvan M, Gümüş ZH, Bhere D, Shah K, Solaroglu I, Bagci-Onder T.
    Oncogene; 2021 May 15; 40(18):3201-3216. PubMed ID: 33767436
    [Abstract] [Full Text] [Related]

  • 8. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
    Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE.
    Cancer Res; 2021 Jun 15; 81(12):3402-3414. PubMed ID: 33687950
    [Abstract] [Full Text] [Related]

  • 9. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R, Albarenque SM, Cool RH, Quax WJ, Mohr A, Zwacka RM.
    Cancer Biol Ther; 2014 Jun 15; 15(12):1658-66. PubMed ID: 25482930
    [Abstract] [Full Text] [Related]

  • 10. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.
    Badr CE, Wurdinger T, Nilsson J, Niers JM, Whalen M, Degterev A, Tannous BA.
    Neuro Oncol; 2011 Nov 15; 13(11):1213-24. PubMed ID: 21757445
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
    Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff MA, Halatsch ME, Crary JF, Canoll P, Siegelin MD.
    PLoS One; 2014 Nov 15; 9(12):e114583. PubMed ID: 25531448
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overcoming TRAIL Resistance for Glioblastoma Treatment.
    Deng L, Zhai X, Liang P, Cui H.
    Biomolecules; 2021 Apr 14; 11(4):. PubMed ID: 33919846
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
    Kondo K, Yamasaki S, Sugie T, Teratani N, Kan T, Imamura M, Shimada Y.
    Int J Cancer; 2006 Jan 01; 118(1):230-42. PubMed ID: 16003725
    [Abstract] [Full Text] [Related]

  • 16. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
    Yoshimura S, Sano E, Hanashima Y, Yamamuro S, Sumi K, Ueda T, Nakayama T, Hara H, Yoshino A, Katayama Y.
    Oncol Rep; 2019 Dec 01; 42(6):2635-2643. PubMed ID: 31638255
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, Fulda S.
    Oncogene; 2009 Sep 03; 28(35):3097-110. PubMed ID: 19597472
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K.
    Proc Natl Acad Sci U S A; 2012 Oct 09; 109(41):16642-7. PubMed ID: 23012408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.